Canaccord raised the firm’s price target on Intellia Therapeutics to $73 from $72 and keeps a Buy rating on the shares. The firm said its Q4 earnings report was straightforward following the company’s early Jan pre- announcement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- NTLA Upcoming Earnings Report: What to Expect?
- Intellia Therapeutics price target lowered to $24 from $38 at Baird
- Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
- Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
- Intellia Therapeutics, ReCode Therapeutics announce collaboration
